Home › Kanser sa Suso › Indiana › Indianapolis
Pag-aaral pangklinika para sa Kanser sa Suso sa Indianapolis, IN
Isang pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Indianapolis. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Nagre-recruitPhase 3
- Community Health Network, Inc, Indianapolis
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Nagre-recruitPhase 3
- Investigative Clinical R of Indiana, Indianapolis
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Nagre-recruitPhase 1
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Nagre-recruitPhase 1/2
- Community Health Network, Indianapolis
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Nagre-recruitPhase 3
- Franciscan Health ( Site 0077), Indianapolis
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Nagre-recruit
- Indiana University, Indianapolis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Nagre-recruitPhase 1
- Indiana University (IU) School of Medicine, Indianapolis
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Nagre-recruitPhase 3
- Indiana University Health University Hospital, Indianapolis
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Nagre-recruitPhase 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Nagre-recruitPhase 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Nagre-recruitPhase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- Community Cancer Center East, Indianapolis
- at 5 pa
HER2 Vaccine for Locally Advanced Breast Cancer
Nagre-recruitPhase 1
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis
Exercise in Metastatic Breast Cancer: EMBody
Nagre-recruit
- Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Nagre-recruitPhase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Health Mooresville, Mooresville · 16 mi ang layo
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Nagre-recruitPhase 2
- Indiana University, Indianapolis
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Nagre-recruitPhase 1/2
- Research Site, Indianapolis
NearWave Optical Molecular Monitoring
Nagre-recruit
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Nagre-recruitPhase 3
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Health Mooresville, Mooresville · 16 mi ang layo
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Nagre-recruitPhase 1
- Community Health Network, Indianapolis
Pag-aaral para sa Kanser sa Suso sa ibang lungsod
- New York City, NY136 pag-aaral
- Houston, TX126 pag-aaral
- Boston, MA112 pag-aaral
- Nashville, TN81 pag-aaral
- Los Angeles, CA73 pag-aaral
- Edison, NJ68 pag-aaral
- St. Louis, MO64 pag-aaral
- Queens, NY64 pag-aaral
- Durham, NC64 pag-aaral
- Chicago, IL59 pag-aaral
- Philadelphia, PA56 pag-aaral
- Dallas, TX55 pag-aaral
Iba pang pag-aaral sa Indianapolis
- Non-Small Cell Lung Cancer32 pag-aaral
- Kanser (lahat ng uri)24 pag-aaral
- Pagkabigo ng Puso23 pag-aaral
- Obesity20 pag-aaral
- Metastatic Cancer19 pag-aaral
- Colorectal Cancer18 pag-aaral
- Kanser sa Ovary17 pag-aaral
- Sakit sa Puso at Ugat ng Dugo17 pag-aaral
- Kanser sa Baga16 pag-aaral
- Type 1 Diabetes14 pag-aaral
- Kanser ng Endometrium14 pag-aaral
- Sakit ni Alzheimer14 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.